“Increasing the probability of success in Phase 2 depends on meticulous planning and a solid risk management strategy.” In this edition of the New Medicines, Novel Insights newsletter, Paul Bridges chats with varying subject matter experts from Parexel on their recommended steps to take in early phase development to mitigate avoidable clinical trial risks. Though there is no simple solution to preventing the unknowns in clinical development, avoiding missteps through strategic planning and foresight can put your company in the best position for success. Read the full article and subscribe for the latest #NovelInsights #ParexelBiotech #EarlyPhase #DrugDevelopment #ClinicalTrials
About us
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove any comments that do not adhere to our guidelines as well as report users who violate the rules of our page.
- Website
-
http://www.parexel.com
External link for Parexel
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Specialties
- Regulatory and product development consulting, early phase clinical research, phase II-III clinical research, late phase clinical research, eClinical solutions, patient and site recruitment, medical device consulting, clinical research organization, pharmacovigilance, biotechnology, biotech, and market access
Locations
-
Primary
2520 Meridian Pkwy
Durham, North Carolina 27713, US
Employees at Parexel
Updates
-
🚀 Two decades of excellence: A clinical operations leader's journey at Parexel 🚀 Cristina DiRenzo's remarkable 20-year career at Parexel is a testament to the power of professional growth, mentorship and dedication. At Parexel, we nurture talent and foster success through: 🔹 A collaborative team environment 🔹 Commitment to delivering high-quality clinical trials to benefit patients 🔹 Diverse career paths tailored to your goals 🔹 Continuous learning and development opportunities Are you passionate about advancing healthcare through clinical research? Join our team and chart your course to success at Parexel! https://insde.co/n15o #ParexelCareers #ClinicalTrials #CareerGrowth #WithHeart
-
Crohn's & Colitis Foundation — one of our 2024 Corporate Patient Advocacy Partners — is a non-profit, volunteer-fueled organization dedicated to finding cures for Crohn's disease and ulcerative colitis and improving the quality of life of children and adults affected by these diseases. 🔷 The Foundation has played a role in every major research breakthrough in IBD, investing more than $500 million in research and 2,500 research projects to date. 🔷 The Foundation educates and supports patients interested in participating in clinical trials to accelerate time to market and expand the number of treatment options for IBD patients. We’re proud to partner with the Foundation this year to learn from Crohn’s disease and ulcerative colitis patients’ first-hand experiences and raise awareness of clinical trials as a treatment option. Learn more about their work: https://lnkd.in/gcysgQj #Crohns #Colitis #ClinicalTrials #PatientAdvocacy #CrohnsColitisFoundation
-
“We believe clinical trials can redress some of the glaring inequalities in patient access to precision oncology” 👏 👏 In this edition of the New Medicines, Novel Insights newsletter, Parexel’s Jakki James and Kristina Reeder review the frustratingly limited patient access in precision oncology, the root causes, and five best practices that can bridge the gap. Learn how oncology experts are empowering patients, sites, and physicians to participate in and accelerate precision oncology. Read the full article below and subscribe to stay up to date on the latest #NovelInsights from our clinical trial newsletter! #PatientsFirst #WithHeart #PrecisionOncology #Oncology
Accelerate precision oncology by empowering and educating patients, sites, and physicians
Parexel on LinkedIn
-
Oncology clinical trials present unique challenges for investigative sites ─ including complex trial designs, challenging eligibility criteria and invasive procedures ─ while trial oversaturation leads to competition for patients and experienced sites. In the third episode of Enabling Successful Sites, Karen McIntyre MSc Clinical Trials and Mitchell Carter, MHA are joined by Angela Galindo, VP, Client Engagement at The START Center for Cancer Care Network. They discuss these challenges, why a site would pass on a study opportunity and how we can make oncology studies less burdensome for both patients and sites. Tune in! 🎙 👉 https://lnkd.in/ePyR3iDQ
-
Last night was filled with hope and inspiration at the Make-A-Wish Eastern North Carolina 2024 Wish Ball! 🌠Parexel team members were moved by the incredible stories of wish kids and their families. We're proud to support Make-A-Wish in their mission to bring light to children facing critical illnesses. 💞 ✨ #ParexelWithHeart #MakeAWish
-
Looking for that next binge-worthy podcast? Three of Parexel's top thought leaders recently joined ACRO’s Good Clinical Podcast to cover trending topics in the clinical research ecosystem: 🌟 S2 Episode 1: "All Hands on Deck" for Empathetic Patient Centricity 🌟 Stacy Hurt 🌻 and Alicia C. Staley discuss turning patient centricity from “buzz word” into action. Hear their personal patient experiences and learn how the upstream patient voice can reduce burden on patients. 🤖 S2 Episode 2: AI in Clinical Research: Decoding Regulatory Expectations 🤖 Stephen Pyke and the FDA's Dr. Tala Fakhouri delve into AI advancements and implications for patients. Discover the FDA’s evidentiary standards for AI, the importance of methodological transparency and how AI can streamline drug development. 🚗 S2 Episode 5: RBQM: Moving Beyond a Belt and Suspenders Approach to Data Quality 🚗 Cris McDavid weighs in on ACRO’s annual RBQM landscape survey findings. Get a sneak peek into five years of RBM/RBQM adoption data and what it means for the future of clinical research. 🎧 Leave a comment below to share your thoughts on these hot topics. Happy listening! 🎙️
-
Novel therapies often don’t meet their revenue expectations, but through informed decision-making, your company can minimize risk and maximize the probability of commercial success. In this edition of the New Medicines, Novel Insights newsletter, Paul Bridges chats with clinical experts from Parexel and Health Advances about the critical decision points in the pre-clinical phase that can ultimately determine the success of your product. Learn how these experts are helping biotech companies reduce risk by advocating for better coordination among departments, with a clear patient focus, at the earliest stages. Create success by planning for it ✅ Read the full article below and subscribe for our latest #NovelInsights #ParexelBiotech #ClinicalDevelopment #EarlyPhase #DrugDevelopment
Speeding life-changing medicines to patients by minimizing risk in the preclinical stage
Parexel on LinkedIn
-
Parexel today announced that its near-term science-based greenhouse gas reduction (GHG) targets have been validated by the Science Based Targets initiative (SBTi). 🎯 🌎 We are proud to be one of the few global CROs with validated science-based targets. 🌏 SBTi validation is a recognition that is widely considered the gold standard for setting and reducing corporate GHG emissions. Read more about Parexel's validated targets and progress on our net-zero roadmap. 👇 Click through below or access the full release here: https://lnkd.in/eMc_2gNY
-
Parexel is proud to partner with The Leukemia & Lymphoma Society in support of #LightTheNight 2024! As the "Shine Light on Patients" sponsor, we're committed to: ❤️ Supporting blood cancer patients and their families 💡 Funding critical clinical research for cures ✨ Shining a light on the darkness of cancer Last year after months of fundraising, Team Parexel made a fantastic showing at Light the Night walks in Cary, N.C. and Boston, Mass. This year, we're excited to do it all again! Join us in our global mission to advance therapies for blood cancer patients. Explore our team page: https://brnw.ch/21wLM8Y #LLS #BloodCancer #ClinicalResearch